Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$30.55
+1.0%
$33.44
$27.66
$121.06
$3.93B1.211.47 million shs2.05 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$48.00
-1.8%
$48.72
$37.63
$51.88
$10.86B0.641.31 million shs796,404 shs
Repligen Corporation stock logo
RGEN
Repligen
$118.88
-1.3%
$121.58
$102.96
$182.52
$6.78B1.05785,214 shs499,746 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$56.22
-1.0%
$53.47
$46.01
$80.95
$8.81B1.42.18 million shs1.81 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+0.99%-2.27%-14.83%-6.86%-61.22%
Qiagen N.V. stock logo
QGEN
Qiagen
-1.81%-2.47%-5.88%+6.90%+7.29%
Repligen Corporation stock logo
RGEN
Repligen
-1.34%-2.20%-0.64%-2.81%-18.59%
Bio-Techne Corp stock logo
TECH
Bio-Techne
-1.00%+3.48%-3.98%+16.33%-20.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.3807 of 5 stars
3.52.00.00.03.51.70.0
Qiagen N.V. stock logo
QGEN
Qiagen
4.0229 of 5 stars
1.12.01.74.53.51.72.5
Repligen Corporation stock logo
RGEN
Repligen
4.8648 of 5 stars
4.41.00.04.53.53.31.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8551 of 5 stars
3.34.01.74.23.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.09
Buy$136.50346.81% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.27
Hold$49.693.51% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.73
Moderate Buy$169.4542.54% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.69
Moderate Buy$69.4223.47% Upside

Current Analyst Ratings Breakdown

Latest QGEN, TECH, RGEN, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $70.00
8/7/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/7/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$63.00 ➝ $61.00
7/30/2025
Repligen Corporation stock logo
RGEN
Repligen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$193.00 ➝ $204.00
7/30/2025
Repligen Corporation stock logo
RGEN
Repligen
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$180.00 ➝ $175.00
7/22/2025
Repligen Corporation stock logo
RGEN
Repligen
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOverweight$160.00
7/22/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$65.00
7/11/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$90.00 ➝ $75.00
7/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$23.66 per shareN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.39$3.15 per share15.24$15.77 per share3.04
Repligen Corporation stock logo
RGEN
Repligen
$634.44M10.54$3.07 per share38.78$36.65 per share3.24
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.22B7.23$2.42 per share23.23$12.24 per share4.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$1.6928.3619.512.5618.30%14.77%8.87%11/5/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.25N/A50.372.22-2.05%4.61%3.24%11/11/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.46122.2228.543.626.02%13.43%10.32%10/29/2025 (Estimated)

Latest QGEN, TECH, RGEN, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12-$1.22-$0.10-$1.22N/AN/A
8/6/2025Q4 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.50$0.53+$0.03-$0.11$315.14 million$316.96 million
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60$0.60N/A$0.44$523.97 million$533.54 million
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40$0.37-$0.03$0.26$174.62 million$182.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%N/A14.79%N/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.57%N/A69.57%N/A

Latest QGEN, TECH, RGEN, and PCVX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/18/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.59%8/18/20258/18/20258/29/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
11.11
11.11
Qiagen N.V. stock logo
QGEN
Qiagen
0.25
1.61
1.35
Repligen Corporation stock logo
RGEN
Repligen
0.26
8.59
7.32
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.18
3.46
2.38

Institutional Ownership

CompanyInstitutional Ownership
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.82 million125.80 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.26 million55.58 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Bio-Techne to Present at Upcoming Investor Conferences
Nuveen LLC Makes New Investment in Bio-Techne Corp $TECH
Bio-Techne Corp $TECH Shares Bought by SVB Wealth LLC
Bio-Techne Corp $TECH Shares Bought by Hsbc Holdings PLC
Bio-Techne Corp $TECH Shares Bought by Korea Investment CORP
Bio-Techne (NASDAQ:TECH) Upgraded at Citigroup

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$30.55 +0.30 (+0.99%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$30.25 -0.30 (-0.99%)
As of 08/27/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$48.00 -0.86 (-1.75%)
Closing price 08/27/2025 03:59 PM Eastern
Extended Trading
$47.20 -0.80 (-1.66%)
As of 08:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$118.88 -1.61 (-1.34%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$120.27 +1.39 (+1.17%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$56.22 -0.57 (-1.00%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$55.90 -0.32 (-0.58%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.